Research programme: CNS disorders therapeutics - Lundbeck

Drug Profile

Research programme: CNS disorders therapeutics - Lundbeck

Alternative Names: LSP1-2111; Lu AF21934

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Lundbeck A/S
  • Class Antibodies; Small molecules
  • Mechanism of Action Metabotropic glutamate receptor 4 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported CNS disorders

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for research development in CNS-disorders in Denmark (SC)
  • 30 Sep 2014 to-BBB technologies is now called BBB Therapeutics
  • 08 Feb 2011 Early research is ongoing in Denmark
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top